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Abstract: To prevent hyperinsulinemia, which may cause atherosclerosis, thiazolidinediones 
(TZDs), also known as insulin sensitizers, are often added to the therapeutic regimen of patients 
with type 2 diabetes who are receiving insulin. The combination of insulin with pioglitazone, 
a TZD, reduces glycoated hemoglobin (HbA1c) by 0.6%–2.1%. The higher the HbA1c baseline 
the larger the therapeutic reduction of HbA1c. This combination therapy has been shown to be 
beneficial even in lean Japanese patients with diabetes. It should be noted that such combination 
therapy is much more useful when the main clinical aim is lowering not postprandial, but fasting 
and nocturnal glycemia. The glycemic-lowering effects of pioglitazone alone occur slowly, 
whereas the addition of insulin to pioglitazone often shows a dramatic glucose-lowering effect. 
Thus, such combination therapy increases the possibility of frequent hypoglycemia within 1 to 
2 months of combining the drugs. Severe hypoglycemia in patients using this therapy is rare. 
Patients treated with combination therapy who show a predominant reduction of glycemia 
often have severe edema; in 10%–20% of patients, combination therapy leads to drug-related 
congestive heart failure (CHF). However, this phenomenon is usually weakened if low doses of 
pioglitazone which are added to insulin therapy (ie, 15 mg/day or even 7.5 mg/day for women). 
It is well known that pioglitazone has an anti-atherosclerotic effect, although it is unclear if 
hyperinsulinemia induces atherogenic changes, either directly or indirectly, by the promotion of 
obesity. Until now, we have not confirmed whether the anti-atherosclerotic effects of pioglitazone 
exceed the supposed disadvantageous action of insulin when used in combination therapy. The 
addition of pioglitazone tends to reduce daily insulin dosages, but study findings have not been 
consistent. Improvement of lipid profiles has also been weak with this combination therapy. 
Long-term trials are needed before any conclusions can be reached concerning atherogenic effects 
of treatment for type 2 diabetes. Combination therapy of even small doses of pioglitazone with 
insulin should be primarily used for patients who achieve insufficient reduction in glycemia 
with insulin monotherapy.
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Introduction
Pioglitazone was developed after troglitazone was removed from the market because 
of hepatotoxicity. In Japan, pioglitazone is the only thiazolidinedione (TZD) available, 
as rosiglitazone has not been approved for commercial use. The TZDs, also called 
glitazones, affect a group of nuclear receptors known as the peroxisome proliferator-
activated receptors (PPAR) and subsequently enhance the effects of insulin1,2 through 
a decrease in insulin resistance, without stimulating insulin release. Although some 
of the activity mechanisms of TZDs have been revealed, the metabolic parameters 
of TZDs in the body have not been fully elucidated. None of the favorable effects of Vascular Health and Risk Management 2010:6 190
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TZDs on: tumor necrosis factor-α; adiponectin; free fatty 
acids; adipocyte size; or fat distribution are directly linked 
to glucose metabolism.
Because the main action of pioglitazone, as with other 
TZDs, is the reconstitution of fatty tissue, its effects on glyce-
mia occur slowly.3 Generally, patients require nearly 6 months 
of therapy before the maximum glucose-lowering effect is 
obtained.3,4 Furthermore, about 50% of patients receiving 
pioglitazone monotherapy are “non-responders,” defined as 
a reduction in glycosolated hemoglobin (HbA1c)  0.7%. 
In many cases, an early reduction in free fatty acids (FFA) 
may predict subsequent decreases in blood glucose levels;4 
however, because FFA values are easily influenced by eating, 
it is not always helpful to use this measurement as the only 
parameter for assessing potential decreases in blood glucose 
levels that will occur with TZDs. Generally, pioglitazone 
monotherapy reduces HbA1c levels by around 1.0%. This 
means that the recent key word “target of treatment,” defined 
as an HbA1c of  7.0%, can be attained when this drug is used 
for patients with an HbA1c  8.0%. However, it is less likely 
to be successful in patients with an HbA1c  8.0%.
Unlike Western populations, Japanese patients with 
type 2 diabetes are more likely to be lean and primarily 
experience insulin deficiency. Thus, in general, sulfonyl-
ureas are relatively effective, and have been the primary 
therapeutic choice for Japanese patients with diabetes. 
In this population, sulfonylureas plus pioglitazone have 
also been shown to be effective. The indication for TZD 
treatment is suggested by a high score on the homeostasis 
model assessment-insulin resistance (HOMA-IR) factor, 
which is calculated from fasting plasma glucose, multiplied 
by fasting insulin concentration. A high HOMA-IR score 
implies that hyperinsulinemia is advantageous for TZD to 
exert its effects. Based on our experience, hyperinsulinemia 
induced endogenous insulin,5 and/or exogenous insulin or 
sulfonylureas, contributes to successful pioglitazone action. 
The addition of pioglitazone to insulin is also widely used 
in lean Japanese patients with type 2 diabetes. In most lean 
Japanese patients with diabetes, the addition of metformin 
has been shown to be less effective for glucose reduction 
than the addition of pioglitazone.
Patients with type 2 diabetes who have inadequate 
responses to oral diabetic agents usually progress to insulin 
therapy. Recent advances in basal-supported oral therapy 
(BOT) have made it easy to start insulin without withdrawing 
oral drugs. In this therapy, other than with pioglitazone, drugs 
that have been used so far are usually not replaced by insulin. 
The addition of a small dosage of pioglitazone together with 
insulin has been shown to be effective; however, there are 
few studies to support this. In contrast to monotherapy with 
glitazone, the combination therapy of glitazone and insulin 
often shows a rapid and large lowering effect in plasma glu-
cose within 1 to 2 months of starting treatment. Insulin may 
be one of the best combination partners for pioglitazone. 
Because the addition of 30 mg pioglitazone frequently 
induces severe hypoglycemic events, a low starting dose of 
pioglitazone (15 mg/day) when added to insulin has been 
recommended in Japan. In cases in which insulin is added 
to pioglitazone therapy, the dose of pioglitazone should be 
decreased beforehand. There is still a need for additional data 
to clarify which insulin is best, that is, rapid type or once daily 
glargine, for combination with pioglitazone. Moreover, we 
have to clarify the treatment target. For example, glycemia 
should not be assessed only by HbA1c, but by nocturnal gly-
cemia and postprandial glycemia levels as well. In addition, 
the reduction of glycemic excursions should be regarded as 
an independent target of glycemia-lowering therapy.
Recently, it was shown that hyperglycemia itself induces 
oxidative stress that may result in apoptosis of β-cells. The 
need to continually increase glucose-lowering therapy 
reflects the progressive nature of diabetes. However, many 
Japanese doctors still hesitate using insulin in patients with 
hyperinsulinemia. Currently, patients with type 2 diabetes 
treated with insulin are more likely to have insulin deficiency 
due to a longer duration of disease in Japan.
The electronic search of scientific and medical journals 
(cross referencing terms of combination, pioglitazone, and 
insulin) yielded 1161 publications, of which only 7 studied 
the efficacy of a combination therapy of pioglitazone and 
insulin, in patients with type 2 diabetes. At present, there 
are few potentially relevant evidence-based publications 
therefore we incorporated all 7 studies into this review 
(Table 1).
Efficacy of the pioglitazone-insulin 
combination therapy
Glycemic control
Previous studies of pioglitazone with insulin therapy reported 
reductions in HbA1c ranging from 0.6% to 2.1% (Table 1). 
Rosenstock and colleagues6 compared the effects of once-
daily pioglitazone (15 or 30 mg) to placebo, in combination 
with insulin, in 566 patients (71%–75% were Caucasian) with 
type 2 diabetes receiving stable insulin regimens for 30 days 
who still had an HbA1c level  8.0%. At the end of a   
16-week treatment patients receiving pioglitazone, 15 or 
30 mg, showed statistically significant decreases in HbA1c Vascular Health and Risk Management 2010:6 191
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levels as compared to baseline (−1.0% and −1.3% 
  respectively; P  0.0001). In that study, subjects were 
obese (BMI 33.2–34.3) and had plasma C-peptide levels 
 0.7 µg/L. Davidson and colleagues7 observed that patients 
receiving pioglitazone (45 mg) showed decreases in HbA1c 
levels of 1.46%, whereas 1.17% in comparison with a group 
treated with 30 mg of pioglitazone. 64% of participants were 
Caucasian with 25% being African American. In that study,7 
individuals with higher baseline HbA1c levels experienced a 
greater reduction in HbA1c levels from baseline; which was 
also shown in a previous study of rosiglitazone.8
The most prominent glucose-lowering effect was described 
by Fernandez,9 who showed a reduction in mean HbA1c levels 
of   2.1% over 36 weeks of treatment in 30 Mexican-Ameri-
can patients; a control group was given a placebo. However, 
this study involved a combination therapy with pioglitazone 
plus continuous subcutaneous insulin infusion in 40% of 
participants. Furthermore, the relatively long-term period of 
study must be noted. As mentioned above, TZDs act slowly 
on glycemia as compared to sulfonylureas. This means that at 
least 6 months of therapy are needed to confirm the efficacy 
of TZDs; if efficacy is determined using HbA1c levels, which 
change within 1 to 2 months after glycemic changes.3 Thus, 
in short-term clinical studies, we may underestimate the 
  glucose-lowering effect of TZDs if HbA1c level is the only 
tool used to assess efficacy.
A link between the elevation of free fatty acid (FFA) 
levels and increasing insulin resistance during the night has 
been reported.10,11 The stimulation effect of TZDs on insulin-
induced FFA use was also reported.12 We have speculated 
that pioglitazone lowers both FFA and glucose levels in the 
early morning.3 Pioglitazone also decreases the nocturnal 
hepatic output of glucose, resulting in lower fasting plasma 
glucose (FPG) levels.13 Japanese patients taking pioglitazone 
had relatively lower FPG and 1,5-anhydroglucitol (1,5-AG) 
levels compared to HbA1c levels.3 FPG is thought to reflect 
mainly nocturnal plasma glucose levels, whereas 1,5-AG, 
which is decreased by hyperglycemia, reflects mainly post-
prandial glycemia.14,15 HbA1c is an indicator of overall daily 
glycemia. Generally, a 1% change in HbA1c corresponds to 
21 mg/dL in FPG. As shown in Table 1, nearly all studies 
had greater decreases in FPG than those suggested by the 
decreases in HbA1c.
The relationship between HbA1c and FPG is useful when 
trying to select the appropriate insulin to use in combination 
with TZDs. With pioglitazone, intensive insulin therapy using 
glargine as a basal insulin,9 or a rapid-acting insulin16 has 
been reported. However, in many trials, the type of insulin 
used is not fully described, and different trials have used 
different products. Patients using biphasic insulin aspart 
30/70 (BIAsp 30) injected twice daily and showed a greater 
reduction in FPG as compared to HbA1c (Ratz and colleagues, 
Table 1 Summary of clinical studies evaluating the effects of combination therapy
Authors  No. of 
cases
Female  
(%)
Age  
(years)
BMI  Design  Combination  Follow up  Reduction
FPG (mg/dl) HbA1c (%)
Rosenstock6   566 52.7 30–75  
(range)
33.2–34.3 V Pio 15 mg  
Pio 30 mg
16 weeks −34.5 
–48.0
−1.0 
–1.3
Mattoo20   263 56.7 58.8  
(mean)
31.8–32.5 BBT Pio 30 mg 6 months −26.1 −0.69
Ratz17   281 40 56 (mean) 29.5 Bl Pio 30 mg 18 weeks −31 −0.64
Davidson7   690 45.4 56.3–56.6 
(mean)
33.2 V Pio 30 mg  
Pio 45 mg
24 weeks −31.9 
–45.8
−1.17 
–1.46
Asnani16   20 — 18–75  
(range)
— R Pio 30 mg 4 months −1.6
Berhanu21   222 — 18–80  
(range)
— V Pio 45 mg  
(titrated)  
(metformin  
involved)
20 weeks −8.6 (insulin  
dose reduction 
study)
−1.6
Fernandez9   30 — — — MDii Pio 45 mg  
(titrated)  
(CSii involved)
36 weeks −67 −2.1
Abbreviations: V, various insulin products; BBT, basal bolus treatment; Bi, biphasic insulin twice a day; R, rapid alone; MDii, multiple daily insulin injection; BMi, body mass index; 
FPG, fasting plasma glucose; Hb1c, glycosolated hemoglobin.Vascular Health and Risk Management 2010:6 192
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Table 1).17 Nevertheless, FPG targets were not achieved even 
though HbA1c targets were reached. Because the portion of 
insulin aspart in BIAsp 30 acts to lower postprandial glu-
cose,18 it is likely that greater glycemic reductions could have 
been achieved if the insulin doses had been increased.19 By 
the end of this trial, the mean BIAsp 30 dose was 0.5 U/kg 
in the plus pioglitazone therapy group and 0.7 U/kg in the 
monotherapy group (without oral diabetic agents).
Lipid profiles
Generally, pioglitazone in combination with insulin therapy 
significantly increases high-density lipoprotein cholesterol 
(HDL) and decreases triglycerides and FFA levels.20,21 
Because triglycerides frequently decrease in parallel with 
glycemic improvement, a reduction in triglyceride level, 
with combination therapy, may not depend primarily on the 
actions of these agents. However, it should be noted that 
unlike pioglitazone, rosiglitazone has been shown to increase 
or have a neutral effect on triglycerides.22,23
LDL levels are not usually influenced by pioglitazone, 
however, LDL particle subfractions change to favorable lipid 
forms. At a given LDL level, smaller LDL particles have been 
associated with greater cardiovascular risk than larger LDL 
particles.24 Pioglitazone shifts LDL particle concentrations 
from small to large and increases the mean LDL particle 
size.7,21 The addition of other TZDs combined with insulin has 
been reported to cause significant increases in LDL.8,25,26
Further trials with similar glycemic endpoints are needed 
to compare the effects of various antidiabetic regimens on 
lipid profiles.
Pleiotropic effects on atherosclerosis
Amelioration of vascular dysfunction and reduction in 
inflammatory biomarkers is not thought to be attributed 
solely to glycemic control or improvement in dyslipemia.9 
TZDs have been shown to result in improved cardiovascular 
outcomes or atherosclerotic biomarkers through various 
mechanisms in diabetic patients.31 In contrast, insulin has 
been suggested to have atherogenic actions, especially 
at high blood concentrations. In combining pioglitazone 
with insulin therapy, it is thought that the anti-atherogenic 
actions of pioglitazone may exceed the negative effects of 
insulin in the development of atherosclerosis.9,20 Recently, 
intensive insulin therapy alone has been found to reduce 
levels of a circulating inflammatory biomarker, highly sen-
sitive C-reactive protein (hsCRP), as well as the formation 
of reactive oxygen and nitrogen species and macrophages, 
thus minimizing the inflammatory response.32–34 This means 
that not insulin itself, but rather acute glycemic fluctuations 
caused by inadequate insulin therapy, may induce vascular 
dysfunction. Glycemic excursions have been regarded as 
an independent risk factor for promoting atherosclerotic 
changes.35,36 Because pioglitazone does not stimulate insulin 
release, it is an antidiabetic drug that does not easily induce 
glucose fluctuations.
Pioglitazone in combination with insulin (n = 142) 
decreased plasminogen activator inhibitor-1 (PAI-1) (−5.10 U/
mL; P  0.001) and hCRP (−1.47 mg/L; P  0.05) compared 
to placebo plus insulin (n = 147) in patients with type 2 dia-
betes mellitus.20 Ethnicity was not described. Both indicators 
increased in the placebo group. Ratz and colleagues17 also 
reported a decrease in PAI-1 levels in the subgroup of patients 
in which the marker was measured in their study. PAI-1 is a 
risk factor for progress of thrombosis.
The addition of pioglitazone to insulin restored endothelial 
function,16 as assessed by flow mediated dilatation (FMD) 
and nitroglycerine-induced dilatation (NID) in patients with 
type 2 diabetes. FMD significantly improved from 10.1% ± 
4.0% to 14.6% ± 6.2% (P = 0.036). NID showed a trend 
toward improvement from 13.3%     ±     8.0% to 18.9%   ±   5.4% 
(P = 0.056). Vascular reactivity, as assessed by changes in 
forearm blood flow (FBF) also improved.9 These data provide 
support, and possible mechanistic insight, into the cardio-
protective results of the PROactive study.37 PRO active was a 
prospective, randomized, controlled trial to compare outcomes 
(mortality, myocardial infarction, and stroke) between pio-
glitazone and placebo, in 5238 patients with type 2 diabetes, 
who had cardiovascular disease.
insulin dose reduction
Although there are some exceptions in protocol designs of 
insulin dose adjustment, many studies7,9,20,21,38 report that pio-
glitazone combined with insulin lead to a reduction in insulin 
dosage together with better glycemic control compared to 
the baseline. In the hyperinsulinemic clamp study, piogli-
tazone demonstrated a 50% increment in insulin-mediated 
glucose disposal.9 Insulin dose reductions from baseline were 
4.5–6.9 U/day for pioglitazone 30 mg/day and 7.3–12 U/day 
for pioglitazone 45 mg/day. These reductions were about 
10% from baseline, which is less than 12%–13% reductions 
seen with troglitazone.8,26,39 However, in many studies, 
insulin dosage was not the primary endpoint and was only 
reduced to prevent hypoglycemia. Thus, it is impossible to 
simply compare the results of studies of insulin dose reduc-
tion. Further head-to-head comparison studies are needed to 
clarify the differences effects of various TZDs.Vascular Health and Risk Management 2010:6 193
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In terms of insulin, there is a lack of evidence concerning 
whether biphasic insulin or glargine (or long-acting analogue 
insulin) should be added to pioglitazone.
In the subanalysis of the PROactive study, addition of 
pioglitazone to insulin resulted in not only insulin dose 
reduction but success in insulin withdrawal in about 10% of 
patients receiving insulin.40 Thus, insulin dose reduction by 
adding pioglitazone may be beneficial both for the preven-
tion of hypoglycemia and of the promotion of atherosclerotic 
changes induced by hyperinsulinemia.
Safety
Hypoglycemia
Although pioglitazone monotherapy is slow to show efficacy, 
its addition to insulin often causes rapid glucose-lowering 
effects. Hypoglycemia usually occurs in the first week or 
weeks after starting combination therapy.38 The frequency of 
hypoglycemia generally is not related to BMI, as it is piogli-
tazone alone. Rather, hypoglycemia with combination therapy 
is attributable to longer duration of diabetes.7 Almost all hypo-
glycemic events were considered mild without deep coma,21,41 
and most were self-treated with caloric intake or could be easily 
avoided by an appropriate reduction in daily insulin dosage. 
A total of 15% of patients receiving 30 mg of pioglitazone with 
insulin reported hypoglycemia.6 The group was composed of 
188 mainly Caucasian patients with a BMI of 34.3. However, 
until now hypoglycemic events have been recorded based on 
data from questionnaires. The use of a continuous glucose 
monitoring system will allow us to track hypoglycemia in 
patients who may be unaware of its occurrence.
Treatment doses should not be lowered or discontinued 
immediately just because of hypoglycemia, because the hypo-
glycemia itself indicates that therapy is lowering blood glucose 
levels. In Japan, pioglitazone 15 mg/day is usually added to 
insulin therapy to avoid hypoglycemia; a dose of 7.5 mg/day 
is used in women. In the case of moderate to severe hypogly-
cemia, a dose of 7.5 mg every other day may be used.
edema and congestive heart failure (CHF)
Plausible mechanisms for the increase in mortality in the Action 
to Control Cardiovascular Risk in Diabetes (ACCORD) trial,42 
in which the majority of patients were treated with rosiglitazone 
and insulin, include a significant weight gain.43 Weight gain can 
be attributed to water retention and/or increase in body fat.
Edema is usually dominant, and severe, in patients who 
respond to TZDs therapy. The overall occurrence of edema 
in combination therapy has been shown to be 10% to 20%.21 
According to the manufacturer’s report, TZDs caused fluid 
retention in 2%–5% of patients receiving monotherapy; this 
increases to 5%–15% among patients receiving concomitant 
insulin therapy.38 However, these incidences may be influ-
enced by differences in the characteristics of the study 
populations, including whether participants have a high risk 
of macrovascular disease.
Edema from TZDs occurs in the lower limbs as well 
as the face; it can also occur in one ankle only.44 These 
symptoms are different from that the edema that usually 
accompanies CHF.
Recent meta-analysis of three randomized controlled 
trials showed an odds ratio (OR) of 2.1 (95% CI 1.08–4.08; 
P = 0.03) for the risk of CHF with TZDs compared with 
placebo.45 Another meta-analysis46 also confirmed that 
patients given TZDs had increased risk for the development of 
CHF (relative risk [RR] 1.72, 95% Cl 1.21–2.42, P = 0.002). 
The results showed no heterogeneity of effects across studies, 
which indicated a class effect for TZDs. It is also well-known 
that insulin can cause water retention in the body through acti-
vating epithelial sodium channels in the collecting tubules.47,48 
Thus, edema from TZDs is both dose-dependent, and greater, 
when these agents are used in combination with insulin6,8,20,21 
than when they are used alone. CHF occurs in approximately 
1.0% of patients receiving pioglitazone.6,49 The US Food 
and Drug Administration-approved prescribing information 
for pioglitazone shows that 1.1% of patients treated with 
pioglitazone plus insulin develop CHF compared with no 
patients in the group receiving insulin alone. Therefore, TZDs 
should be used with caution in patients with diabetes who 
are predisposed to heart failure, as well as in the elderly or 
in those receiving insulin.50 Some studies have reported that 
pulmonary edema develops after treatment with TZDs.51,52 
Older age, longer duration of diabetes, and the use of high 
doses of insulin (82, 140 and 740 U/day) appear to be risk 
factors for the development of pulmonary edema.38
Edema or fluid retention can cause CHF. However, only in 
a minority of edema cases induced by TZD treatment are asso-
ciated with CHF. Furthermore, fluid retention following the 
use of TZDs is not accompanied by decreased left ventricular 
dysfunction.53,54 Pioglitazone induces elevation of plasma brain 
natriuretic peptide (BNP) level.55 In most cases, BNP increases 
slightly, or moderately, (to 70–100 pg/mL)56 which is the 
value that suggests the presence of CHF. Recently, “vascular 
leak syndrome” has been noted after treatment with TZDs. 
Although the mechanisms of this phenomenon are not clear, 
an enhancement in endothelially-mediated vasodilatation57 or 
an increase in vascular permeability through augmentation of 
vascular endothelial growth factor58,59 are suggested causes.Vascular Health and Risk Management 2010:6 194
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Further studies are required to establish the safety of 
glitazone and insulin in combination to treat patients with 
diabetes and CHF and/or cardiovascular events.60,61
Patients receiving TZDs, including pioglitazone, show 
remarkable weight increases of about 5 kg.62,63 The weight 
gain occurs during the first weeks of treatment and tend to 
stabilize thereafter. In some cases, increases in body weight 
still continue up to two to three years. Weight gain has also 
been observed with TZDs in combination with insulin,6 
and was strongly correlated with decreases in HbA1c levels 
(r = 0.8844; P = 0.002). The reason TZDs cause weight 
gain may be related to increases in total body fluid volume 
caused by edema. However, other causes may also contribute 
to weight gain, including increased fat accumulation and 
redistribution.38
Adipogenesis and increases in body fat
Treatment with TZDs often causes an increase in body fat. 
Unlike in Western countries, most patients with diabetes 
in Japan are not obese. Weight gain can be seen mainly in 
patients with obesity and correlates with the drug’s effec-
tiveness in lowering glycemia. Stimulation of PPARγ is 
supposed to increase feeding and adipogenic efficiency; 
however, details regarding these effects remain unclear. 
Troglitazone was reported to lower plasma leptin levels and 
increase hunger in humans.64
Many studies65–67 have now shown that TZDs increase the 
amount of subcutaneous fat, whereas the amount of visceral 
fat is unchanged. These differential effects may be related 
to the observation that PPARγ are more highly expressed 
in subcutaneous than omental preadipocytes.68 It is also 
known that the differentiating capacity of subcutaneous 
adipocyte precursor cells is higher than that of visceral fat 
precursor cells.
The addition of TZDs to insulin is likely to augment 
the fat-accumulating effect of each agent. For rosiglitazone 
and insulin combination therapy, body weight was shown 
to increase significantly, but the waist-to-hip ratio did not 
change.8 Weight gain was more common in patients treated 
with BIAsp 30 plus pioglitazone (8% of patients) than in 
those treated with BIAsp 30 monotherapy (3%) or gliben-
clamide plus pioglitazone (2%).17
The negative effects of weight gain on glycemic 
  control and metabolism on a long-term basis have not been 
  extensively investigated. Obesity may induce secondary 
failure of TZD therapy. Although the frequency of second-
ary failure is thought to be relatively less than that seen with 
sulphonylurea, a significant re-elevation of HbA1c has been 
observed 56 weeks after starting pioglitazone therapy in a 
Japanese phase II study (unpublished data). Losing dietary 
therapy should be followed closely in patients being treated 
with TZDs.
Liver injury
The combination of pioglitazone with insulin does not signifi-
cantly alter the relationship between pioglitazone treatment and 
liver damage in patients with type 2 diabetes. In a multicenter 
study, no patient in the pioglitazone 15 mg plus insulin group 
had an alanine aminotransferase (ALT) level 3 × the upper 
limit of normal.6 In contrast to troglitazone, pioglitazone has 
no potential hepatotoxicity in patients with type 2 diabetes, 
including those treated with insulin.38
Bone fracture
Bone fracture risk with rosiglitazone has emerged in A 
Diabetes Octcome Progression Trial (ADOPT).69 Recent 
meta-analysis showed that long-term TZDs, including 
pioglitazone, use doubles (OR 2.23, 95% CI 1.65–3.01; 
P  0.001) the risk of fractures among women with type 2 
diabetes.70 TZDs exposure was also associated with signifi-
cant change in bone mineral density at the lumbar region of 
the spine and the hip.70 TZDs increased adiposity of bone 
marrow, decreasing osteoblast activity, and increased bone 
resorption.71,72 The meta analysis involved around 45,000 
participants, thus, the number of patients involved under-
going combination therapy was high. The study suggested 
a long-term effect of the drug, which may not be avoided 
by slow-dose titration. Whether combination therapy with 
insulin increases the risk of fractures is still unclear and will 
require further long-term study.
New regimen, basal supported  
oral therapy (BOT)
Success in attaining strict glycemic control in newly diag-
nosed diabetes will influence long-term outcomes.73 In fact, 
aging and hyperglycemia are major causes of oxidant stress, 
which stimulates apoptosis of pancreatic β-cells. Because 
β-cells have weak regenerative potential it is important to 
reduce hyperglycemia as early as possible after diabetes is 
diagnosed. Insufficient achievement of glycemic control 
can induce glycemic fluctuations and further development 
of diabetic complications.
It has been reported that insulin monotherapy for patients 
with type 2 diabetes does not lead to HbA1c levels  7.0%, 
especially when used for long periods. The reason for this lack 
of change in HbA1c levels may be related to the factors discussed Vascular Health and Risk Management 2010:6 195
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above. There is yet no set algorithm on how to add oral anti-
diabetic agents to insulin monotherapy in patients with type 2 
diabetes. Although, the addition of TZDs to patients who have 
failed to respond to insulin monotherapy may be beneficial, as 
in those patients who have strong insulin resistance; metformin 
or glimepiride are the most frequently chosen agents, probably 
in an effort to avoid adverse effects, such as weight gain. It was 
reported that patients who had oral antidiabetic drugs added to 
their insulin therapy were less likely to attain glycemic control 
than those treated with insulin monotherapy.74 The effectiveness 
and safety of adding pioglitazone to patients in whom combina-
tion therapy with insulin, sulfonylureas, and metformin have 
failed has not been evaluated.
Alternatively, insulin therapy for patients for whom 
oral agents have failed, called basal supported oral therapy 
(BOT), has gained increasing support because of its ease of 
use and safety.75 It should be noted, however, that a consen-
sus on its algorithm has not been reached, and the definition 
of this therapy remains unclear. The addition of insulin to 
a monotherapy drug may be even included in this therapy. 
In a recent consensus algorithm76 reported by the ADA and 
EASD, only the combination of metformin plus insulin is 
recommended in Tier 1 therapy. Use of pioglitazone in the 
BOT regimen has not been assessed.
In the BOT regimen, if a long-acting analogue insulin 
is chosen for insulin treatment, management of postpran-
dial hyperglycemia may be insufficient. The algorithm 
recommended by the ADA and EASD lacks data regarding 
postprandial hyperglycemia except for the glucagon-like 
peptide-1 (GLP-1) analogue used in Tier 2 therapy. Unlike 
in the United States, α-glucosidase inhibitors (α-GI) are 
frequently used in Japan. Combination therapy of α-GI and 
insulin is beneficial to prevent glucose excursions and/or 
hypoglycemia. The addition of glinides to insulin is also 
useful. Pioglitazone may be a good partner for these drugs 
to prevent postprandial hyperglycemia. However, additional 
studies are needed to support the addition of pioglitazone to 
rapid, ultra rapid analogue or mixed type insulin.
Conclusions
The combination of pioglitazone with insulin may enhance 
glycemic control beyond the level achieved by insulin alone. 
It may also help to reduce insulin dosages in patients already 
receiving insulin. From a safety perspective, pioglitazone 
should be started at a low dose in patients already receiving 
insulin, or be reduced to a lower dose in patients who are 
already receiving pioglitazone who are going to start insulin 
therapy. If frequent hypoglycemia and/or edema occur with 
the additional of pioglitazone, the drug can be withdrawn and 
started again at a lower dose or once every other day after 3 to 
4 months. If CHF occurs, pioglitazone should be stopped. 
Mild CHF and edema are usually manageable by reducing 
the dose of pioglitazone and/or adding a diuretic. Monitoring 
of plasma BNP may be useful to predict the occurrence CHF, 
because many patients with diabetes have asymptomatic car-
diac failure. Patients should also be told to avoid dietary salt 
if they experience edema and should be instructed to follow a 
low-calorie diet. Despite the need for prudence, combination 
therapy with pioglitazone and insulin should be considered 
for the patients with poor glycemic control.
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